Latest Headlines

  1. Headlamp Health Launches Lumos AI To De-Risk Neuroscience Drug Development 1/7/2026

    Headlamp Health today announced the launch of Lumos AI®, a comprehensive decision-support platform designed to help drug developers address the complexity that has long stalled neuroscience progress.

  2. BostonGene And Astrazeneca Announce Strategic Collaboration To Advance Foundation Model-Driven Oncology Development 1/6/2026

    BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform.

  3. Novoron Bioscience Awarded $2.5M NIH/NIA SBIR Grant To Accelerate Alzheimer's Drug Discovery With Human Brain Organoids 1/6/2026

    Novoron Bioscience, a San Diego-based biotechnology company developing therapies for neurodegenerative diseases and neurological injury, has received a $2.5 million Small Business Innovation Research (SBIR) grant from the National Institute on Aging at the National Institutes of Health.

  4. Variant Bio Launches Inference, The World's First Agentic AI Genomic Drug Discovery Platform 1/6/2026

    Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug discovery platform.

  5. YD Bio Enters Into MOU To Merge With EG BioMed, Advancing DNA Methylation–Driven AI Platforms For Cancer Diagnostics And Drug Development 1/6/2026

    YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics.

  6. Biosplice Announces The Submission Of Its New Drug Application (NDA) To The FDA For Lorecivivint (LOR) To Treat Knee Osteoarthritis 1/6/2026

    Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that it has submitted its NDA to the FDA for approval of its novel therapy for the treatment of knee osteoarthritis (“OA”).

  7. Ascentage Pharma Announces IND Clearance By The U.S. Food And Drug Administration For BTK Degrader APG-3288 1/6/2026

    Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration (FDA) and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies.

  8. Kelun-Biotech Receives Investigational New Drug Approval For ITGB6-Targeted ADC SKB105 From The NMPA 1/5/2026

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.

  9. Insilico Medicine Announce US$888M Multi-Year Collaboration With Servier For Drug Discovery And Development In Oncology 1/4/2026

    Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation.

  10. Axsome Therapeutics Announces FDA Acceptance And Priority Review Of Supplemental New Drug Application For AXS-05 For The Treatment Of Alzheimer's Disease Agitation 12/31/2025

    Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheimer’s disease agitation, and has granted the application Priority Review designation.